GLG News by Physicians who Treat Dry Eye (US)

Biodem (ASX:BDM) is conducting a a Phase I/II trail involving a 10 day course of subcutaneous injection of a peptide in the treatment of diabetic macular edema.  The results of this trial which is being conducted abroad in Russia will be available in November 2007. Although promising...

LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA.  This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis.  In a field where there are few approved treatment modalities, this could...

Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena.  The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...

Similar to Bausch & Lomb's reaction to last year's ReNu with MoistureLoc's recall, AMO's CEO has blamed their consumers' poor contact lens hygiene habits for Complete MoisturePlus' recent problems with Acanthamoebic Keratitis.  Is there any truth to this statement, or is he just...

Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina.  A total of 33 cases of RPE tear after treatment with...

This "fast track" exposure for the LX211 may allow for a new type of uveitis treatment by the end of 2008. the hope is to decrease toxicity, and increase effectivity.

This glaucoma drug efficacy crossover study shows that bimatoprost (Lumigan) from AGN lowers intraocular pressure better than latanoprost (Xalatan) from PFE in a special subset of glaucoma patients (exfoliative glaucoma).  The difference is only 1 mm Hg which may be statistically significant will...

AMO issued their recall of their MoisturePlus solution in late May, but are some contact lens patients still unaware and still using this solution?  The answer is YES.

Bayer and Regeneron are moving forward with their Phase 3 Trial called the VIEW involving VEGF Trap for the treatment for choroidal neovascularization in Age Related Macular Degeneration.  The implications are large for a billion dollar market that is currently dominated by Lucentis (DNA).

Current management is not responsive to my needs as a practitioner, nor my patient's needs. Let someone else try to make a venerable name good again.